Published in Proc Natl Acad Sci U S A on July 11, 2011
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol (2014) 3.66
Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61
A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell (2013) 3.53
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
Organoid models of human and mouse ductal pancreatic cancer. Cell (2014) 2.99
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov (2011) 2.49
High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet (2015) 2.35
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data (2014) 1.76
ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med (2014) 1.66
Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol (2014) 1.64
RNAi screening comes of age: improved techniques and complementary approaches. Nat Rev Mol Cell Biol (2014) 1.54
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep (2014) 1.34
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (2016) 1.31
Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol (2014) 1.28
Stable RNA interference rules for silencing. Nat Cell Biol (2014) 1.26
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell (2016) 1.26
Epithelial ovarian cancer experimental models. Oncogene (2013) 1.23
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A (2013) 1.22
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol (2012) 1.21
Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell (2014) 1.20
Integration of genomic data enables selective discovery of breast cancer drivers. Cell (2014) 1.11
Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One (2014) 1.10
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med (2015) 1.10
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09
CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem (2011) 1.08
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Lean Big Data integration in systems biology and systems pharmacology. Trends Pharmacol Sci (2014) 1.05
Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps. Nat Protoc (2014) 1.04
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol (2013) 1.03
A simple method for analyzing actives in random RNAi screens: introducing the "H Score" for hit nomination & gene prioritization. Comb Chem High Throughput Screen (2012) 1.00
High-resolution network biology: connecting sequence with function. Nat Rev Genet (2013) 0.99
Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics (2014) 0.99
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A (2014) 0.99
A comparative genomic approach for identifying synthetic lethal interactions in human cancer. Cancer Res (2013) 0.95
The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford) (2016) 0.95
The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep (2011) 0.94
An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates. Assay Drug Dev Technol (2012) 0.92
The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci (2013) 0.92
Integrated analysis of recurrent properties of cancer genes to identify novel drivers. Genome Biol (2013) 0.91
Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens. Comb Chem High Throughput Screen (2013) 0.91
Pax8 has a critical role in epithelial cell survival and proliferation. Cell Death Dis (2013) 0.89
Integrative genomic and functional profiling of the pancreatic cancer genome. BMC Genomics (2013) 0.89
Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics (2014) 0.89
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics (2016) 0.89
The kinome 'at large' in cancer. Nat Rev Cancer (2016) 0.88
Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem (2014) 0.88
SANTA: quantifying the functional content of molecular networks. PLoS Comput Biol (2014) 0.88
Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov (2016) 0.88
A primer on using pooled shRNA libraries for functional genomic screens. Acta Biochim Biophys Sin (Shanghai) (2012) 0.87
An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene (2013) 0.87
Collateral Lethality: A new therapeutic strategy in oncology. Trends Cancer (2015) 0.87
Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin (2015) 0.86
SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation. Cancer Res (2015) 0.86
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene (2013) 0.86
An extended set of yeast-based functional assays accurately identifies human disease mutations. Genome Res (2016) 0.85
Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. Nucleic Acids Res (2015) 0.85
PAX Genes in Cancer; Friends or Foes? Front Genet (2012) 0.85
Probing the epigenome. Nat Chem Biol (2015) 0.85
A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells. BMC Cancer (2014) 0.84
Pair-Box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer. Br J Cancer (2012) 0.84
Empowering biologists with multi-omics data: colorectal cancer as a paradigm. Bioinformatics (2014) 0.84
Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife (2017) 0.84
An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene (2013) 0.83
Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet (2015) 0.83
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol (2014) 0.83
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget (2015) 0.83
ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. Bioinformatics (2015) 0.82
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun (2016) 0.82
Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat Rev Genet (2016) 0.82
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther (2015) 0.82
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1). Oncotarget (2011) 0.82
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
Scaling up the systematic hunt for mammalian genetic interactions. Nat Methods (2013) 0.81
Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) (2013) 0.80
An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma. PLoS One (2015) 0.80
Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecol Oncol (2012) 0.80
The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res (2014) 0.80
Public data and open source tools for multi-assay genomic investigation of disease. Brief Bioinform (2015) 0.80
Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol (2013) 0.80
Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. Bioinformatics (2016) 0.79
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol (2017) 0.79
Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. Cancer Metab (2015) 0.79
PAX8 expression in ovarian surface epithelial cells. Hum Pathol (2015) 0.79
Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions. Drug Discov Today Technol (2014) 0.79
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
MYB function in normal and cancer cells. Nat Rev Cancer (2008) 3.56
Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet (2004) 3.21
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet (1998) 2.75
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Sox9 coordinates a transcriptional network in pancreatic progenitor cells. Proc Natl Acad Sci U S A (2007) 2.15
Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol (2006) 1.96
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene (2011) 1.92
Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci (2008) 1.77
Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol (2004) 1.75
Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One (2010) 1.54
Pax genes in embryogenesis and oncogenesis. J Cell Mol Med (2008) 1.37
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol (2011) 1.36
Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res (2005) 1.33
c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene (2006) 1.33
Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology (2006) 1.25
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
GenePattern 2.0. Nat Genet (2006) 29.07
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol (2010) 18.44
The mammalian epigenome. Cell (2007) 18.13
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet (2003) 16.51
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 16.47